NEW YORK, April 23, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
PDC Energy, Inc. (NASDAQ: PDCE), SandRidge Energy, Inc. (NYSE: SD),
Thermo Fisher Scientific, Inc. (NYSE: TMO), Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) and Questcor Pharmaceuticals,
Inc. (NASDAQ: QCOR). Private wealth members receive these notes
ahead of publication. To reserve complementary membership, limited
openings are available at:
http://www.analystsreview.com/1468-100free.
--
PDC Energy, Inc. Analyst Notes
On April 10, 2014, PDC Energy, Inc.
(PDC Energy) announced plans to release its Q1 2014 financial
results before the market opens on May 6,
2014, followed by a conference call with investors to
discuss the performance the same day at 11:00 a.m. ET. Analysts at Zacks Investment
Research expect the Company to report adjusted diluted EPS of
$0.33. In the preceding quarter ended
December 31, 2013, the Company had
surprised the street by reporting adjusted diluted EPS of
$0.44 versus net loss of $4.25 in the corresponding quarter of the prior
year. The full analyst notes on PDC Energy are available to
download free of charge at:
http://www.analystsreview.com/1468-PDCE-23Apr2014.pdf
--
SandRidge Energy, Inc. Analyst Notes
On April 14, 2014, SandRidge Energy,
Inc. (SandRidge Energy) announced that it will release its Q1 2014
shareholder update and financial results after the close of trading
on the NYSE on May 7, 2014. The
Company will also host a conference call to discuss the results the
following day at 8:00 am CDT.
According to Zacks Investment Research, the consensus EPS estimate
for the quarter is $0.02. In the
previous quarter ended December 31,
2013, the Company had posted adjusted net income of
$14.9 million, or $0.03 per diluted share, compared to adjusted net
income of $35.3 million, or
$0.06 per diluted share, in Q4 2012.
The full analyst notes on SandRidge Energy are available
to download free of charge at:
http://www.analystsreview.com/1468-SD-23Apr2014.pdf
--
Thermo Fisher Scientific, Inc. Analyst Notes
On April 14, 2014, Thermo Fisher
Scientific, Inc. (Thermo Fisher)
introduced a new peristaltic pump that enables researchers working
in bioprocessing environments to achieve the precision and
reliability needed to improve their processes. According to the
Company, the Thermo Scientific Miniflex peristaltic pump delivers
an expanded flow range of up to 370 mL per minute, allowing
researchers to effectively dispense low- and high-volume fluids
with repeatability and accuracy on a scale previously not offered
by pumps of equivalent size. Thermo
Fisher stated that the new Miniflex also offers small
instrument footprint, offering easy integration into small space
applications and continuous tubing which reduces the risk of
contamination and leakage. The full analyst notes on
Thermo Fisher are available to
download free of charge at:
http://www.analystsreview.com/1468-TMO-23Apr2014.pdf
--
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 11, 2014, Regeneron
Pharmaceuticals, Inc. (Regeneron) announced that it will report its
Q1 2014 financial and operating results on May 8, 2014, at 8:30 a.m.
ET, before the U.S. financial markets open. According to
Bloomberg, the consensus adjusted diluted EPS estimate for the
quarter is $2.34. In the previous
quarter ended December 31, 2013, the
Company delivered a positive surprise of 7.47% in its adjusted EPS
of $2.24. Also in Q4 2013, the
Company's revenues of $610.4 million,
which represented a growth of 47.2% YoY, surpassed the market
expectations. Analysts polled by Bloomberg had expected the
Company's revenues at $581.8 million
in Q4 2013. The full analyst notes on Regeneron are available to
download free of charge at:
http://www.analystsreview.com/1468-REGN-23Apr2014.pdf
--
Questcor Pharmaceuticals, Inc. Analyst Notes
On April 17, 2014 Questcor
Pharmaceuticals, Inc. (Questcor Pharmaceuticals) announced in a
press release that it is partnering with the National Kidney
Foundation to become a National Sponsor of Kidney Walk, which is
the country's largest walk to raise money and awareness for kidney
disease. As stated by the Company, through this partnership,
Questcor will support more than 85 Kidney Walks across the country.
Steve Cartt, Questcor's COO said,
"Questcor is very pleased to partner with the National Kidney
Foundation as a National Corporate Sponsor of Kidney Walk. As a
company, we are committed to serving the needs of kidney patients,
their families and the healthcare providers who care for them. Our
support of the Kidney Walk helps the Foundation serve its mission
to raise awareness of kidney disease and to provide lifesaving
programs that directly impact kidney patients and their families."
The full analyst notes on Questcor are available to
download free of charge at:
http://www.analystsreview.com/1468-QCOR-23Apr2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content
to our exclusive membership. We are constantly hiring researchers,
writers, editors and analysts to add to our team and become better
than yesterday. If being a part of a fast growing community with an
edge in today's market sounds interesting to you, then sign-up
today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review